Clinical trials: Hyperactivity
Attention-Deficit Hyperactivity Disorder(ADHD)
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.
- Trial name
- NCT07086313
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 315 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention-Deficit Hyperactivity Disorder(ADHD)
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
The purpose of this study is to evaluate the safety of long-term administration of mainly high doses of EB-1020 over 52 weeks in pediatric ADHD patients.
- Trial name
- NCT07087327
- Testing
- EB-1020 (Centanafadine) low dose, EB-1020 (Centanafadine) high dose
- Where
- Japan
- Volunteers
- 180 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Attention Deficit Disorder With Hyperactivity
A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels
The purpose of this study is to evaluate the dose strength equivalence of to-be-marketed (TBM) centanafadine (CTN) once daily (QD) extended release (XR) when administered as 2 capsules of 164.4 milligrams (mg) or as a single…
- Trial name
- NCT07253441
- Testing
- CTN XR (TBM), CTN SR, CTN XR (Clin)
- Where
- 2 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
The primary objective was to evaluate the safety and tolerability of four doses of SPN-810 in children with ADHD and persistent serious conduct problems.
- Trial name
- NCT00626236
- Testing
- SPN-810
- Where
- 9 sites in United States
- Volunteers
- 78 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder
A Pilot Study on Efficacy of Digital Therapeutic NDTx-02 for Executive Function in Children and Adolescents With ADHD or ASD
The purpose of this study is to explore the preliminary safety and effectiveness of the digital therapeutic device 'NDTx-02' in supporting improvements of executive function in children and adolescents diagnosed with…
- Trial name
- NCT07242625
- Testing
- NDTx-02 + TAU, TAU
- Where
- 3 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Neudive Inc.
Attention Deficit Hyperactivity Disorder
A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)
The primary objectives are to investigate the effect of atomoxetine on impulsivity after single dose and at steady state measured by the total score of Barrett Impulsiveness Scale version 11 (BIS-11) and Short Urgency…
- Trial name
- NCT05278104
- Testing
- Zentiva®
- Where
- 5 sites in Germany
- Volunteers
- 63 people
- Sponsor
- Boehringer Ingelheim
Attention-deficit Hyperactivity Disorder (ADHD)
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
This trial is a Phase 1 study in adolescents with ADHD and genetic disruptions impacting genes in the metabotropic glutamate receptor (mGluR) network.
- Trial name
- NFC1-GREAT (NCT02286817)
- Testing
- NFC-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Attention Deficit Hyperactivity Disorder (ADHD)
A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
The main aim of the study is to find out how frequently adults with at least one psychiatric condition have ADHD (but have not been diagnosed with ADHD before) and to describe the quality of life of these adults who have been…
- Trial name
- LANDSCAPE (NCT04943796)
- Where
- 14 sites in Canada, Germany and 4 more
- Volunteers
- 224 people
- Sponsor
- Takeda
Attention Deficit Hyperactivity Disorder
ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder
This is a randomized, double-blind, flexible dose-titration, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of ADZENYS XR-ODT compared to placebo in children with ADHD.
- Trial name
- NCT07169162
- Testing
- ADZENYS XR-ODT
- Where
- United States
- Sponsor
- Aytu BioPharma, Inc.
ADHD - Attention Deficit Disorder With Hyperactivity
Brain Stimulation and Attention Control in Children With ADHD
The goal of this clinical trial is to learn if brain stimulation can help children ages 6 to 12 with attention-deficit/hyperactivity disorder (ADHD) improve their attention and self-control.
- Trial name
- NCT07182344
- Testing
- Intermittent Theta Burst Stimulation to Right DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type
Multi-center, Single Blinded, RCT, Pivotal Study to Evaluate the Efficacy and Safety of DTx to Improve ADHD
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, impulsivity, and impaired executive functioning.
- Conditions
- ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined Type, ADHD
- Trial name
- NCT07173439
- Testing
- Model Name: EMT-SR01;red
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- EMOTIV
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.
Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
The primary objective of this study was to evaluate the efficacy and safety of Mexidol® film-coated tablets (125 mg) compared to a placebo in children aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
- Trial name
- MEGA (NCT06854601)
- Testing
- Mexidol
- Where
- 14 sites in Russia
- Volunteers
- 333 people
- Sponsor
- Pharmasoft
Attention Deficit/Hyperactivity Disorder (ADHD)
To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.
An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study in healthy adult human subjects under fasting conditions.
- Trial name
- NCT07098585
- Testing
- Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Attention Deficit Disorder With Hyperactivity
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
The purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of participants diagnosed with…
- Trial name
- NCT04132557
- Testing
- Methylphenidate, Lisdexamfetamine, Atomoxetine
- Where
- United States
- Volunteers
- 430,000 people
- Sponsor
- Janssen Research & Development, LLC
ADHD - Combined Type, ADHD Predominantly Inattentive Type
NeuroTrainer Cognitive Training For Academic Focus
This clinical trial aims to evaluate the feasibility and efficacy of NeuroTrainer cognitive training in improving attentional and executive control functions in students with and without attention-related difficulties.
- Conditions
- ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive
- Trial name
- NCT06512974
- Testing
- NeuroTrainer
- Where
- 3 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- NeuroTrainer
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
ADHD
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
The goal of this clinical trial is to evaluate the efficacy and safety of NRCT-101SR compared to placebo in adult patients with ADHD aged 18 years and older.
- Trial name
- NCT05683249
- Testing
- NRCT-101-SR
- Where
- 9 sites in United States
- Volunteers
- 223 people
- Sponsor
- Neurocentria, Inc.
Attention Deficit/Hyperactivity Disorder
An Efficacy and Safety Study w/ Azstarys® in Children 4-12 Years of Age With ADHD
This is a multicenter, dose-optimized, randomized, double-blind, placebo controlled, efficacy and safety study with Azstarys® in children 4 to 12 years of age with attention-deficit/hyperactivity disorder (ADHD).
- Trial name
- KP415P01 (NCT05685732)
- Testing
- Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
- Where
- 20 sites in United States
- Volunteers
- 246 people
- Sponsor
- Corium, Inc.
Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD
The purpose of this study was to evaluate the effect of 4-week SPN-810 treatment on brain functioning in patients aged 8-12 years with ADHD and associated feature of impulsive aggression (IA).
- Trial name
- NCT03638466
- Testing
- Functional Magnetic Resonance Imaging (fMRI), Magnetic Resonance Spectroscopy (MRS), Point Subtraction Aggression Paradigm (PSAP) Task
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Supernus Pharmaceuticals, Inc.